U.S. markets open in 2 hours 20 minutes
  • S&P Futures

    4,442.75
    -3.00 (-0.07%)
     
  • Dow Futures

    34,740.00
    +66.00 (+0.19%)
     
  • Nasdaq Futures

    15,246.00
    -72.75 (-0.47%)
     
  • Russell 2000 Futures

    2,249.30
    +5.30 (+0.24%)
     
  • Crude Oil

    74.83
    +0.85 (+1.15%)
     
  • Gold

    1,748.50
    -3.20 (-0.18%)
     
  • Silver

    22.56
    +0.14 (+0.60%)
     
  • EUR/USD

    1.1710
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    18.63
    0.00 (0.00%)
     
  • GBP/USD

    1.3701
    +0.0020 (+0.15%)
     
  • USD/JPY

    110.9710
    +0.2860 (+0.26%)
     
  • BTC-USD

    43,739.59
    +563.28 (+1.30%)
     
  • CMC Crypto 200

    1,091.05
    -12.01 (-1.09%)
     
  • FTSE 100

    7,056.32
    +4.84 (+0.07%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

Novartis, Molecular Partners Initiate Global Trial For COVID-19 Treatment

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Novartis AG (NYSE: NVS) along with Molecular Partners AG (OTC: MLLCF) is kicking off a Phase 2/3 EMPATHY study of DARPin therapeutic candidate, ensovibep (MP0420), to treat COVID-19.

  • The program is investigating the safety and efficacy of ensovibep in patients with COVID-19, who are in the early stages of infection, to prevent worsening symptoms and hospitalization. The study will enroll 400 patients in Phase 2 to identify a dose with optimal safety and activity, with initial results anticipated in August 2021.

  • Then Phase 3 will move ahead with an additional 1,700 patients with results anticipated in H1 2022.

  • Pending the positive outcome, it would pave the way for Novartis to seek expedited approval via the FDA’s Emergency Use Authorization (EUA).

  • Initial findings from the Phase 1 trial of ensovibep found it safe and well-tolerated with no significant adverse events. Predictable exposure was seen post-administration, confirming the expected half-life of two to three weeks.

  • Novartis paid $69 million in October 2020 to collaborate with Molecular Partners on ensovibep and MP0423.

  • The preclinical work for MP0423 is still ongoing and led by Molecular Partners.

  • Price Action: NVS shares closed at $89.16 on Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.